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Abstract
Background: The possible effect of transcranial direct current stimulation (tDCS) in improving cognitive function is
clear from studies involving pre-dementia stage mild cognitive impairment (MCI). However, the application of tDCS
in actual clinical practice entails repeated hospital visits almost every day for treatment. The objective of this study
is to confirm the possibility of self-application of tDCS at home by elderly patients with declined cognitive function
and the significant clinical effect of tDCS administered at home.
Methods/design: This study will be conducted in 20 elderly people aged 60 to 80 years with complaints of
subjective memory impairment while maintaining general functions with limited activities of daily living. This study
involves a cross-over design that will include 2-week active or sham stimulation of both dorsolateral prefrontal
cortexes (left, anode; right, cathode) randomly with a 2-week wash-out phase. Changes in cognitive function will be
evaluated using visual recognition tasks and neuropsychological tests. In this study, tDCS will be carried out by
each patient at his/her home and its safety and suitability will be evaluated.
Discussion: In this study, patients will apply a portable tDCS, developed for home use, for more than 2 weeks. Such
studies can contribute to the use of tDCS as a realistic therapy. In addition, the utility of home-based tDCS will be
confirmed by application of tDCS at home by the elderly with declined cognitive function. Furthermore,
confirmation of tDCS as a significant therapeutic method can facilitate treatment of Alzheimer’s dementia at an
early stage, including MCI.
Trial registration: Clinical Research Information Service (CRIS), KCT0002721. Registered on 9 March 2018.
Keywords: Transcranial direct current stimulation, Mild cognitive impairment, Home-based, Cross-over study, Brain
stimulation
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Background
Mild cognitive impairment (MCI) refers to declined cog-
nitive function below normal range while maintaining
successful independent daily living [1]. Declined cogni-
tive function in MCI falls between cognitive deterior-
ation caused by aging and dementia due to Alzheimer’s
disease or other [2]. MCI might be a precursor to de-
mentia [3], which is an important topic for clinical trials
investigating dementia treatment and prevention. Trans-
cranial direct current stimulation (tDCS) is a therapeutic
modality indicated for declined cognitive function,
including MCI.
tDCS is used to control neuronal excitability by transmit-
ting a small amount of current via an electrode patch on
the scalp. Anodal stimulation increases cortical activity by
drawing the resting potential close to the threshold poten-
tial while cathodal stimulation inhibits excitability by separ-
ating the resting potential from the threshold potential [4].
As control over brain activity affects brain functions such
as behavior, emotion, and information processing, clinical
application of tDCS for depression, multiple sclerosis, and
other central nervous system disorders is under investiga-
tion by several clinical groups [5–7].
The effect of tDCS on cognitive function has been estab-
lished in various clinical trials and experimental studies. In
a study conducted in healthy adults, visuospatial working
memory performance status improved after anodal tDCS
[8]. Another study has shown that tDCS can result in tem-
porary but meaningful improvement in aging-related cogni-
tive decline [9]. In tDCS and repeated transcranial
magnetic stimulation (rTMS) studies conducted in individ-
uals with declined cognitive function, improvement of cog-
nitive function has been reported [9–13]. In a study by
Meinzer et al. [11] in particular, anodal tDCS increased task
performance and reversed pathological brain activity and
connectivity patterns. Boggio et al. [13] confirmed that the
performance in visual memory recognition task is improved
after tDCS treatment of dorsolateral prefrontal cortex in a
study of patients with Alzheimer’s dementia. In these stud-
ies, tDCS has been applied temporarily or without sufficient
repetition. Therefore, it is necessary to evaluate the effect of
repeated tDCS sessions on cognitive function in patients
with MCI.
tDCS is user-friendly, relatively cheap, and tolerable
compared to similar non-invasive brain stimulating
devices such as rTMS [14]. In addition, no serious side
effects have been reported with tDCS, thus encouraging
home use [15]. In fact, home-based clinical application
of tDCS has been investigated in a number of studies in
depression, chronic pain, multiple sclerosis, tinnitus, and
mild vascular dementia [16–20]. However, to the best of
the author’s knowledge, home-based clinical application
of tDCS has not been investigated in MCI. Furthermore,
the same equipment used in hospitals is also used in
previous home-based tDCS studies. Therefore, the
development of smaller, low-weight, and automated de-
vices and additional studies investigating the suitability
and safety of home-based application are needed.
This study will investigate the effect of tDCS on cognitive
function and the safety of self-application by instructing
patients with MCI to self-administer tDCS repeatedly using
the device developed for home-based application. This
study is designed to determine whether repeated tDCS
stimulation at home can improve cognitive function by
visual recognition task and neuropsychological tests in
patients with MCI. It will also determine whether patients
with MCI can safely administer tDCS by themselves at
home.
Methods/design
This study will involve patients diagnosed with MCI
who visited Gangnam Severance Hospital and Severance
Hospital, tertiary referral centers and the teaching hos-
pital of Yonsei University. All participants will be in-
formed of experimental goals of this study. Written
informed consent will be obtained. This study protocol
was approved by the Korean Ministry of Food and Drug
Safety and complied with ethical standards based on
Declaration of Helsinki.
Inclusion criteria
Selection criteria are: 1) adults aged between 60 and 80
years; and 2) patients with cognitive decline from previous
performance levels but which do not interfere with capacity
for independence in everyday activities. Cognitive decline
but not dementia will be determined using the Korean ver-
sion of the Global Deterioration Scale (GDS; 2–3 points)
[21] or Clinical Dementia Rating (CDR; if 0.5) and MMSE-
DS (Korean version of MMSE for Dementia Screening;
higher than the cut-off according to age and academic
background) [22]. Independence in activities of daily living
will be determined according to Seoul-Instrumental Activ-
ities of Daily living score [23] (< 7 points). Complaints of
cognitive decline induced by depression will be evaluated
using K-GDS (Korean version of Geriatric Depression
Scale) (≤ 8 points) [24]. Final clinical diagnosis will be con-
ducted by skilled psychiatrists using DSM-V (Diagnostic
Statistical Manual of Mental Disorder, fifth edition) criteria
for mild neurocognitive disorder.
Exclusion criteria
Exclusion criteria are as follows: 1) history of dementia
or intellectual disability; 2) use of cognitive enhancers
(donepezil, rivastigmine, galantamine, and memantine);
3) reversible medical conditions associated with poten-
tial cognitive impairment (e.g., history of vitamin B12
deficiency or hypothyroidism); 4) diagnosis of current al-
cohol dependence or DSM-V [25] disorders associated
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with the use of alcohol; 5) epilepsy; 6) clinically severe
disorders involving cardiovascular, digestive, respiratory,
endocrine, and central nervous systems; 7) history of cere-
brovascular surgery; 8) problems associated with direct
current stimulating electrode caused by scalp malforma-
tion, inflammatory reaction, or other dermatological prob-
lem; and 9) other contraindications for tDCS medical
device (e.g., metal plate inserted into cephalus, etc.). In
addition, patients who participated in other clinical studies
within the past 30 days, who expressed difficulty in reading
or having a conversation due to vision and hearing issues
after wearing assistance, and those who are ineligible for
this study based on other medical judgment will be ex-
cluded from this study. Use of other psychiatric medication
except cognitive enhancers and general medications will be
permitted.
Outcome measures
Primary outcomes
This study will determine cognitive improvement by
using visual recognition tasks similar to those described
previously [12, 13] in which tDCS is administered to pa-
tients with Alzheimer’s dementia. In the encoding phase,
screens with two, four, six, and eight stimulations are
displayed for 10 s, respectively. Participants are required
to memorize pictures displayed on each screen. After a
1-s interval, the test phase is started and the specific
stimulus is displayed. Participants are required to re-
spond as rapidly as possible whether or not the stimulus
involves the picture seen in the encoding phase. Similar
to previous studies, our task comprises an encoding
phase and a test phase. In contrast to previous studies,
black-and-white icon stimuli will be used to provide a
more intuitive and simple format. Objects, human body
parts, and animals that are generally seen in daily life
will be used. The test phase will comprise three, six,
eight, and ten test trials of two, four, six, and eight pic-
tures, respectively, in the encoding phase.
Secondary outcomes
In addition to visual recognition tasks, standardized
neuropsychological tests and questionnaires will be used
to determine cognitive improvement and changes in
daily life, which will be assessed by 1) letter-number se-
quencing; 2) spatial span; 3) clinical global impression
(CGI) [26]; 4) neuropsychiatric inventory [27]; and 5)
Korean version of the Consortium to Establish a Registry
for Alzheimer’s Disease Neuropsychological Assessment
Battery (CERAD-K) [28].
Covariate measures
Additionally, a questionnaire will be used to determine
factors that influence the therapeutic utility of tDCS.
The questionnaire includes the following: 1) Edinburgh
Handedness Inventory [29]; 2) State Anxiety Inventory
(STAI-X-1) [30, 31]; 3) Montgomery-Asberg Depression
Rating Scale (MADRS) [32, 33]; 4) Korean version of the
Hamilton Depression Scale (K-HDRS) [34]; and 5)
Hamilton Anxiety Scale (HAM-A) [35].
Intervention
tDCS stimulation protocol
The electrode will be located by placing the anode and
cathode on the left dlPFC (F3) and the right dlPFC (F4),
respectively, similar to the procedure described by Bog-
gio et al. [13]. To facilitate placement of the electrode at
home, a skilled investigator will provide a picture of a
desirable location taken with a smart phone. Similar to
previous studies [12, 13, 36], active stimulation will in-
crease the current for 30 s. The current is then kept at 2
mA for 29min. The current is then decreased for 30 s.
Sham stimulation will be maintained for 29 min without
current flow by increasing current for 30 s followed by a
decrease for 30 s. Both conditions will be
self-administered by the subject for 30 min each day for
14 consecutive days.
Home-based tDCS device
This study will be conducted using a tDCS device (Ybrain,
MINDD STIM, http://www.ybrain.com/) designed for ap-
plication at home. The device consists of 1) a docking sta-
tion for stimulation setup and information output, 2) a
miniaturized module for saving the performance record
that is compatible with a smart phone, and 3) a smart
phone. The module works with any smart phone, al-
though we will use a research smart phone to control the
experimental environment. The module transfers the
stimulation performance records to a server linked to the
docking station via a compatible smart phone that can be
remotely monitored by the investigator. The electrode of
the device, which is circular in form and measures 67mm
in diameter (or 22mm thick) will be used after inserting a
disposable sponge into the patch supporter followed by
treatment with saline solution. The electrode will be
inserted into the pre-selected hole of the cap for fixing on
the head and linking to the module (Fig. 1).
Safety strategy for home-based tDCS application
Several technologies will be used to safely conduct tDCS
independently at home. The stimulation protocol is not
modifiable in the module by the subject as it is access-
ible only with a password via the station. The module
contains a skin-contact recognition function. Therefore,
the device automatically starts upon recognition of the
patch adhering to the skin. The output automatically
stops upon recognition of the patch being detached from
the skin, even during stimulation. The device stops im-
mediately when the current output exceeds the limit
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allowed by the module. A smart phone application de-
tects module operation. A self-inspection questionnaire
for safety assessment will be administered upon comple-
tion of the operation. In addition, 24-h contact informa-
tion is provided via the smart phone. In case of any
suspected side effects, the subject is expected to visit the
hospital immediately.
Training and support for participants
Even though the device has a safety guarantee, it might
be meaningless if the user is not familiar with its usage.
Therefore, checklist-based training will be conducted by
using the device for practice without stimulation. Subjects
who have completed all items of the checklist will be
allowed to use the device for the study after three training
sessions and the final test. Remote support will be provided
via a remote-control program integrated in the smart
phone and video calling will be used to facilitate the study.
Design and procedure
Trial design
This study was designed as a 9-week, multicenter, random-
ized, double-blinded, cross-over clinical study. All subjects
will undergo a 2-week treatment phase twice (treatment I
and treatment II) with a 2-week washout period. A follow-
up assessment will be conducted 2 weeks after completion
of the second treatment phase (treatment II; Fig. 2). In
treatment I, either active or sham tDCS will be adminis-
tered. In treatment II, tDCS under different conditions will
be administered.
Randomization and blinding
A random group assignment list was created by statisticians
who are not involved in data collection using PASS 12
(NCSS, LLC, Kaysville, Utah, USA, https://www.ncss.com/
). Participants are allocated 1:1 to the active first group and
sham first group. The device manager will set up the device
according to the assignment list in order of participant’s
registration number. The same single device can be set to
sham or active status using the administration menu. Be-
cause only the device manager, who will not contact the
participants, knows the assignment list and the password
required to access the administration menu, other investi-
gators and participants will remain blind to it. This masks
investigators and enables the use of fewer devices.
Study schedule
Assessments at each visit are listed in Table 1 & Fig. 3.
Details of each phase are as follows:
1. Screening phase: Only participants with written
consent will be screened. Subjects who meet the
inclusion criteria will be randomized.
2. Treatment phase I (visit 1 to visit 2): During visit 1
(T1), a visual recognition task and a
neuropsychological test will be conducted with
baseline data for efficacy assessment. After the
outcome measures are taken, including covariance
measurements, training for tDCS use will be
conducted for subjects or their caregivers by using
a tDCS device for practice and a check list. The
first clinical device application and assessment of
side effects will be conducted for subjects who have
passed the test for tDCS use. Starting from the day
after the first visit, the subject (or his/her caregiver)
will use the device once daily for 2 weeks (a total of
14 days). It is recommended to use the device at
specific times (e.g., immediately after face washing
in the morning). Information about time and period
of application by the subject are automatically saved
in the device. Researchers will monitor the
information remotely at certain times of the day
and will call if tDCS is not applied.
3. Wash-out phase (visit 2 to visit 3): The subject will
be required to visit the hospital 2 weeks after visit
T1 for efficacy assessment. Subsequently,
appropriate use of the device by subjects will be
assessed by the investigator using a tDCS device for
practice. A log of the returned device will be
printed by the device manager for records so that
Fig. 1 Image of the device provided to study participants. a Module
and electrode while wearing cap. b tDCS module and electrode. c
Smart phone with application
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blinding is maintained. Later, a 2-week wash-out
phase will be conducted.
4. Treatment phase II (visit 3 to visit 4): The subject
will be required to visit the hospital at 4 weeks after
visit T1. Similar to treatment I, training sessions
will be conducted and proficiency with the device
will be assessed. Also similar to treatment 1, the
device will be used at home after returning from
the hospital. After returning home, subjects will
apply the device once daily for 2 weeks (14 days).
5. Follow-up phase: Subjects will be asked to visit the
study institution at 6 weeks after visit T1.
Appropriateness of device application and efficacy
assessment will be evaluated by the investigator.
Finally, a follow-up assessment will be conducted
during a study visit at 2 weeks after the last treat-
ment visit (T4).
Statistical analysis
Sample size
The sample size was calculated based on results reported
by Boggio et al. [12]. Boggio et al. [12] administered active
or sham tDCS once daily for 5 days to patients with
Alzheimer’s dementia and compared their performance
for visual recognition tasks before and at 1month after
treatment. Based on differences in mean correct response
rate (ε = 11.61, σd = 11.62; 1:1 allocation ratio per group)
in the previous study, a sample size was estimated to
obtain at least 90% power (1 − beta = 0.9) to detect a treat-
ment difference of 11.61 (SD 11.62 of change) in visual
recognition task scores at a significance level of 0.05 (α =
0.05). A total of 14 persons (seven per sequence) were
selected by PASS 12 (NCSS, LLC, Kaysville, Utah, USA,
https://www.ncss.com/) as the smallest sample size. This
study targeted a total of 20 subjects (10 per group) consid-
ering a drop rate of 30%.
Statistical methods
For primary efficacy assessment, differences in correct
response rate in the visual recognition task before and
after treatment will be calculated. Differences between
active and sham setups will be analyzed by a general
linear model [37] to assess major (treatment), period
(time), and carry-over effects. For secondary efficacy
assessment, analysis of variance (ANOVA) of changes in
each sub-item of CERAD-K will be conducted. Only the
results of the participants who completed the interven-
tion will be included in these efficacy analyses, but the
side effects will be reported for all participants.
Discussion
Despite promising results reported by studies investigat-
ing cognitive improvement using non-invasive brain
stimulation methods, their actual use in clinical practice is
still limited. Reasons restricting their clinical use may
include: 1) the long-term effect cannot be confirmed as
most previous studies only monitored changes after single
and temporal treatment; 2) although the effect of > 2-week
repetitive application was observed in several studies,
patients were asked to visit hospital every day in order to
reproduce such effects in actual practice. In this study, pa-
tients will be asked to use miniaturized, automated tDCS
Fig. 2 Study design and method
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STUDY PERIOD
Enrolment Allocation Post-allocation Close-out
TIMEPOINT** -t1 0 t1 t2 t3 t4 tx
ENROLMENT:
Eligibility screen X
Informed consent X
Allocation X
INTERVENTIONS:
Active tDCS
Sham tDCS
Washout X
ASSESSMENTS:
Baseline variables
MMSE-DS/GDS/CGI1)
/CGS/S-IADL/K-GDS X X X X X X
Vital sign2) X X X X X X
Medical symptom/sign X X X X X X
Concomitant medication 
check X X X X X X
Outcome variables
Visual recognition task X X X X X
Neuropsychological test.3) X X X X X
Other data variables
Questionnaire4) X X X X X
Adverse event check X X X X X
1) CGI: not measured at screening.
2) Sitting systolic/diastolic BP, pulse and temperature were measured.
3) Neuropsychological tests: CERAD, Letter Number Sequencing, Spatial Span 
4) Questionnaires for investigator, subject and guardian were administered for efficacy assessment.
For investigator: MARDRS/HAMD/HAMA
For subject: STAI/PSQI/Hand Function Rating Scale
For guardian: NPI
Fig. 3 Schedule of enrolment, interventions, and assessments
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that is available for self-administration at home under
remote surveillance. If the elderly with cognitive decline
can use tDCS at home, patients with diverse diseases with-
out cognitive impairment can use tDCS safely as well.
Our findings may suggest that home-based tDCS is a
practical treatment for patients, thus addressing limi-
tations of non-invasive brain stimulation methods de-
scribed previously.
Previous results have indicated a high incidence of de-
mentia in elderly patients with MCI compared to the
general elderly population. According to Petersen et al.
[1, 3], approximately 10–15% of the aging population
progresses to Alzheimer’s disease while 80% of elderly
with MCI present symptoms of dementia after 6 years.
However, drug therapies that delay progress from MCI
to dementia or improve cognitive function are unknown
[38]. Considering that the elderly are generally vulner-
able to side effects of drugs and drug–drug interactions
due to polypharmacy, non-drug therapies are in demand.
The potential of tDCS to significantly improve cognitive
function in MCI provides a significant treatment alterna-
tive for not only patients with MCI, but also those with
early-stage Alzheimer’s dementia. In addition, improving
cognitive function is expected to help reduce social care
burdens and improve patients’ subjective quality of life
by maintaining their independence.
Cognitive function consists of various interacting do-
mains, with specific domains influenced greatly by disease
or therapy. This study seeks to use visual recognition tasks
as well as standardized comprehensive neuropsychological
assessments and symptom questionnaires for efficacy as-
sessment. Therefore, it is expected to unravel complex pat-
terns of change in cognition and symptoms related to the
use of tDCS. In addition, it may facilitate the assessment of
neuropsychological characteristics of patients with signifi-
cant response to tDCS.
Lastly, applications and technologies for symptom and
side effect assessment as well as remote support that are in-
tegrated into the smart phone in this study are applicable
not only to tDCS studies, but also to other clinical trials.
Such home-based clinical trial systems utilizing established
technologies are inexpensive to install. They are highly ex-
pandable due to compatibility with a wide range of devices
and applications. These methodologies are relevant to eld-
erly patients facing difficulty with hospital visits. They are
also useful for clinical studies investigating the effect of
physical activity using ambulatory monitoring devices.
This study has some limitations. First, the study is a
small-scale cross-over study. Although cross-over design
enables exploratory studies in a relatively small number
of patients, a large-scale study is needed to validate the
clinical effect. Second, a 2-week wash-out period in this
study might be insufficient given that studies demon-
strating a consistent effect with tDCS are still unavail-
able. The effect of tDCS has been reported to continue
in patients with Alzheimer’s disease [12]. To overcome
this limitation, we will analyze the carry-over effect using
a general linear model. Third, psychological factors in
the elderly associated with the use of a smart phone may
influence this study. The elderly who experience cogni-
tive decline may feel burdened by having to learn how to
use the new devices. This can influence their compliance
with the study protocol. The interface and devices
should be optimized for use in the elderly population
and verified in further studies.
In summary, this study will facilitate the application of
tDCS in MCI as a home-based, self-administered inter-
vention and a realistic therapy. Furthermore, confirmation
Table 1 List of tests conducted at each visit
Phase Screening Treatment I Washout Treatment II Follow-up
Day 0 1 14 28 42 56
Visit S1 T1 T2 T3 T4 F1
Visual recognition task O O O O O
Neuropsychological testa O O O O O
Basal symptom and sign O O O O O O
Vital signb O O O O O O
MMSE-DS/GDS/CGIc/CGS/S-IADL/K-GDS O O O O O O
Questionnaired O O O O O
Concomitant medication check O O O O O O
Adverse event check O O O O O
aNeuropsychological tests: CERAD, letter number sequencing, spatial span
bSitting systolic/diastolic blood pressure, pulse, and temperature were measured
cCGI: not measured at screening
dQuestionnaires for investigator, subject, and guardian were administered for efficacy assessment
For investigator: MARDRS/HAMD/HAMA
For subject: STAI/PSQI/Hand Function Rating Scale
For guardian: NPI
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of tDCS as a significant therapeutic method will facilitate
treatment for Alzheimer’s dementia at an early stage, in-
cluding MCI (Additional file 1).
Trial status
Recruitment of participants started in March 2018 and
will be completed in July 2019. The manuscript reports
protocol version 1.1 (November 24, 2017).
Additional file
Additional file 1: SPIRIT 2013 checklist: Recommended items to address
in a clinical trial protocol and related documents. (DOC 122 kb)
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